KNSA

Kiniksa Pharmaceuticals, Ltd. [KNSA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KNSA Stock Summary

Top KNSA Correlated Resources

KNSA


Top 10 Correlated ETFs

KNSA


Top 10 Correlated Stocks

KNSA


In the News

06:57 22 Mar 2023 KNSA

The Top 7 Growth Stocks in Biotech

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

12:48 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

08:28 22 Mar 2023 KNSA

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting

Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

11:17 22 Mar 2023 KNSA

Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

11:37 22 Mar 2023 KNSA

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

02:45 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.

KNSA Financial details

Company Rating
Buy
Market Cap
795.88M
Income
167.01M
Revenue
211.95M
Book val./share
5.71
Cash/share
2.75
Dividend
-
Dividend %
-
Employees
215
Optionable
No
Shortable
Yes
Earnings
01 May 2023
P/E
4.7
Forward P/E
-
PEG
-0.23
P/S
3.71
P/B
1.98
P/C
4.12
P/FCF
-144.35
Quick Ratio
4.32
Current Ratio
5.16
Debt / Equity
0.16
LT Debt / Equity
0.01
-
-
EPS (TTM)
2.4
EPS next Y
-
EPS next Q
-0.43
EPS this Y
-214.78%
EPS next Y
-
EPS next 5Y
-194.01%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-37.58%
EPS Q/Q
-98.02%
-
-
-
-
SMA20
-15.38%
SMA50
-23.2%
SMA100
-8.48%
Inst Own
42.92%
Inst Trans
-0.24%
ROA
36%
ROE
59%
ROC
-0.02%
Gross Margin
90%
Oper. Margin
-3%
Profit Margin
79%
Payout
-
Shs Outstand
70.06M
Shs Float
27.52M
-
-
-
-
Target Price
-
52W Range
7.36-17.195
52W High
-33.41%
52W Low
+61.71%
RSI
32.19
Rel Volume
1.04
Avg Volume
374.52K
Volume
390.23K
Perf Week
-5.59%
Perf Month
-20.51%
Perf Quarter
-1.65%
Perf Half Y
6.89%
-
-
-
-
Beta
-0.079973
-
-
Volatility
0.16%, 0.94%
Prev Close
1.8%
Price
11.32
Change
-0.53%

KNSA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000.563.17
Net income per share
-3.49-2.99-2.61-2.32.64
Operating cash flow per share
-2.74-2.93-2.21-1.840.08
Free cash flow per share
-2.92-2.99-2.21-2.140.08
Cash per share
10.44.325.232.662.75
Book value per share
9.454.175.042.75.71
Tangible book value per share
9.454.175.042.425.45
Share holders equity per share
9.454.175.042.75.71
Interest debt per share
00.030.110.090.09
Market cap
829.99M597.79M1.09B807.15M1.04B
Enterprise value
758.01M550.86M985.71M690.73M922.55M
P/E ratio
-8.04-3.69-6.77-5.115.67
Price to sales ratio
00020.944.72
POCF ratio
-10.25-3.77-8-6.39178.98
PFCF ratio
-9.62-3.7-7.99-5.5182.28
P/B Ratio
2.972.653.54.362.62
PTB ratio
2.972.653.54.362.62
EV to sales
00017.924.19
Enterprise value over EBITDA
-7.35-3.4-6.41-4.482.58
EV to operating cash flow
-9.36-3.48-7.22-5.47158.87
EV to free cash flow
-8.78-3.41-7.2-4.71161.79
Earnings yield
-0.12-0.27-0.15-0.20.18
Free cash flow yield
-0.1-0.27-0.13-0.180.01
Debt to equity
0.150.130.120.260.16
Debt to assets
0.130.110.110.210.14
Net debt to EBITDA
0.70.290.70.76-0.33
Current ratio
7.378.6810.464.385.16
Interest coverage
00000
Income quality
0.780.980.850.80.03
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0002.580.3
Intangibles to total assets
0000.080.04
Capex to operating cash flow
0.070.0200.16-0.02
Capex to revenue
000-0.530
Capex to depreciation
-18.5-1.55-0.12-8.67-0.04
Stock based compensation to revenue
0000.650.11
Graham number
27.2616.7617.2111.8218.43
ROIC
-0.65-1.08-1.3411.28-0.69
Return on tangible assets
-0.32-0.64-0.46-0.740.42
Graham Net
8.963.784.622.032.12
Working capital
271.2M213.8M301.4M151.62M195.99M
Tangible asset value
279.27M225.42M311.94M165.79M377.9M
Net current asset value
271.05M212.52M295.72M148.68M179.54M
Invested capital
00.010.020.030.01
Average receivables
0001.99M8.32M
Average payables
6.07M8.31M3.1M1.19M4.88M
Average inventory
0001.84M12.64M
Days sales outstanding
00037.7420.99
Days payables outstanding
00074.93125.93
Days of inventory on hand
000147.4344.34
Receivables turnover
0009.6717.39
Payables turnover
0004.872.9
Inventory turnover
0002.481.06
ROE
-0.37-0.72-0.52-0.850.46
Capex per share
-0.18-0.060-0.30

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-09-302021-12-312022-03-312022-09-30 2022-12-31
Revenue per share
0.180.270.471.430.89
Net income per share
-0.44-0.53-0.363.230.06
Operating cash flow per share
-0.42-0.27-0.530.89-0.17
Free cash flow per share
-0.42-0.28-0.530.89-0.17
Cash per share
2.922.642.112.892.75
Book value per share
3.122.682.45.535.71
Tangible book value per share
2.832.42.135.265.45
Share holders equity per share
3.122.682.45.535.71
Interest debt per share
0.10.090.080.10.09
Market cap
782.07M811.79M687.22M891.67M1.04B
Enterprise value
598.63M695.37M629.3M722.62M922.55M
P/E ratio
-6.4-5.59-6.810.9958.25
Price to sales ratio
64.6643.3121.358.9916.8
POCF ratio
-27.43-42.99-18.6514.37-89.78
PFCF ratio
-27.38-42.42-18.6514.37-90.03
P/B Ratio
3.654.394.132.322.62
PTB ratio
3.654.394.132.322.62
EV to sales
49.4937.119.557.2914.91
Enterprise value over EBITDA
-19.95-19.65-27.8515.22.62
EV to operating cash flow
-21-36.82-17.0811.65-79.7
EV to free cash flow
-20.96-36.34-17.0811.65-79.92
Earnings yield
-0.04-0.04-0.040.250
Free cash flow yield
-0.04-0.02-0.050.07-0.01
Debt to equity
0.180.260.390.20.16
Debt to assets
0.150.210.280.170.14
Net debt to EBITDA
6.113.292.56-3.56-0.33
Current ratio
6.324.383.954.285.16
Interest coverage
00-685.85144.140
Income quality
0.930.521.460.28-2.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
1.591.460.650.170.23
Intangibles to total assets
0.080.080.080.040.04
Capex to operating cash flow
00.01000.01
Capex to revenue
0-0.01000
Capex to depreciation
-0.08-0.380-0.04-0.14
Stock based compensation to revenue
0.510.330.190.060.1
Graham number
5.595.644.4420.042.87
ROIC
0.242.6-0.252.08-1.46
Return on tangible assets
-0.13-0.17-0.120.510.01
Graham Net
2.432.021.582.022.12
Working capital
183.09M151.62M148.4M185.32M195.99M
Tangible asset value
194.55M165.79M147.24M365.51M377.9M
Net current asset value
178.7M148.68M134.04M165.87M179.54M
Invested capital
0.030.030.030.020.01
Average receivables
2.89M3.6M16.71M011.91M
Average payables
2.9M1.76M2.63M04.68M
Average inventory
5.99M4.64M8.45M018.11M
Days sales outstanding
23.9919.1382.3110.1318.41
Days payables outstanding
53.6443.4824.4111.44-115.28
Days of inventory on hand
182.3485.5395.41113.83-315.21
Receivables turnover
3.754.71.098.884.89
Payables turnover
1.682.073.697.87-0.78
Inventory turnover
0.491.050.940.79-0.29
ROE
-0.14-0.2-0.150.580.01
Capex per share
00000

KNSA Frequently Asked Questions

What is Kiniksa Pharmaceuticals, Ltd. stock symbol ?

Kiniksa Pharmaceuticals, Ltd. is a BM stock and trading under the symbol KNSA

What is Kiniksa Pharmaceuticals, Ltd. stock quote today ?

Kiniksa Pharmaceuticals, Ltd. stock price is $11.32 today.

Is Kiniksa Pharmaceuticals, Ltd. stock public?

Yes, Kiniksa Pharmaceuticals, Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap